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Cinacalcet use and the risk of 
cardiovascular events, fractures 
and mortality in chronic kidney 
disease patients with secondary 
hyperparathyroidism
Marie Evans  1,2, Shona Methven1, Alessandro Gasparini  5, Peter Barany  1, Kate Birnie3, 
Stephanie MacNeill3, Margaret T. May3, Fergus J. Caskey1,3 & Juan-Jesus Carrero4
With the aim to expand the randomized controlled trial evidence of cinacalcet treatment to the 
unselected, general chronic kidney disease (CKD) population we analysed a large inception cohort 
of CKD patients in the region of Stockholm, Sweden 2006–2012 (both non-dialysis, dialysis and 
transplanted) with evidence of secondary hyperparathyroidism (SHPT). We used marginal structural 
models to account for both confounding by indication and time-dependent confounding. Over 37 
months, 435/3,526 (12%) initiated cinacalcet de novo. Before cinacalcet initiation, parathyroid hormone 
(PTH) had increased progressively to a median of 636ng/L. After cinacalcet initiation, PTH declined, as 
did serum calcium and phosphate. In total, 42% of patients experienced a fatal/non-fatal cardiovascular 
event, 32% died and 9% had a new fracture. The unadjusted cardiovascular odds ratio (OR) associated 
with cinacalcet treatment was 1.01 (95% confidence interval: 0.83, 1.22). In the fully weighted model, 
the cardiovascular odds was lower in cinacalcet treated patients (OR 0.67: 0.48, 0.93). The adjusted ORs 
for all-cause mortality and for fractures were 0.79 (0.56, 1.11) and 1.08 (0.59, 1.98) respectively. Our 
study suggests cinacalcet treatment improves biochemical abnormalities in the wider CKD population, 
and adds real-world support that treating SHPT with cinacalcet may have beneficial effects on 
cardiovascular outcomes.
Chronic kidney disease (CKD) is a common disease with a life-time risk in the United States as high as 59%1. 
Those affected by CKD have an increased risk of cardiovascular disease and death already from early CKD stages2. 
The increased levels of parathyroid hormone (PTH), often seen in patients with CKD, has been associated with 
the increased risk of cardiovascular events, fractures and mortality3. In those with end-stage kidney disease, 
secondary hyperparathyroidism (SHPT) accelerates vascular calcification and subclinical atherosclerosis4,5 and 
further lead to hyper-dynamic bone disease and osteitis fibrosis cystica (renal osteodystrophy).
Cinacalcet acts on the calcium-sensing receptor and effectively decreases parathyroid hormone (PTH) levels6. 
In addition, cinacalcet can also improve phosphate balance and reduce hypercalcemia7,8. Furthermore, the com-
bined treatment with cinacalcet and vitamin D delays the progression of valvular, aortic and coronary calcifica-
tion score9. Yet, these favourable changes in biochemical and proxy markers have not been followed by significant 
reductions in hard clinical outcomes. The Evaluation Of Cinacalcet hydrochloride therapy to Lower cardiovas-
cular events (EVOLVE) trial was inconclusive and failed to show any statistically significant effect on its primary 
outcome, a composite of cardiovascular events and death10. However, predefined secondary and post-hoc analy-
ses of the EVOLVE trial suggested beneficial effects both in general and in subgroups. As a consequence of these 
mixed results, it has been proposed that whilst cinacalcet could be used as one of several drugs to improve the 
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achievement of biochemical control in chronic kidney disease related mineral bone disorder as recommended by 
international guidelines11, it should not to be used with the purpose of reducing cardiovascular outcomes and/or 
improving survival12.
As with several other randomized controlled trials in nephrology which later showed negative results, the 
EVOLVE study was preceded by observational data indicating a positive effect of the treatment13,14. However,, 
although studies using traditional statistical models could adjust for confounding by indication they will inher-
ently suffer from time-dependent confounding. In observational studies, treatments are often given more fre-
quently to individuals with severe illness who have a higher mortality risk. Consequently, we need to adjust for 
differences between treated and non-treated. We also have to consider that people who initiate treatment are more 
likely to be those with a progressive disease. Traditional methods allow adjustment for time-updated measure-
ments, but do not take into account that the current level of the risk factor also is influenced by previous decisions 
to treat or not to treat. In the example of cinacalcet, PTH level is both a determinator of the risk of treatment 
and a risk factor for death. Also, the current PTH level is affected by treatment/non-treatment. Studies of the 
association between cinacalcet and outcome therefore require statistical models which consider time-dependent 
confounding.
Marginal structural models (MSM) are advanced statistical models which adjust for both baseline confound-
ing by indication and time-dependent confounding. The MSM approach result in less biased results if applied 
to cohorts where rich information on characteristics used to allocate treatment status and predict outcomes are 
available in repeated measurements over time. Carefully performed observational studies have proved to be a 
useful adjunct to randomized trials in order to translate and reproduce their results in wider and more heter-
ogeneous populations15,16. There are now numerous examples where MSMs have been used to guide clinical 
decision-making; most of them are connected to HIV research17,18. In this study we aimed to analyse if treatment 
with cinacalcet in CKD patients with SHPT was associated with improved cardiovascular outcomes, all-cause 
mortality or fractures compared with non-treatment. We undertook this study in a complete healthcare utili-
zation cohort in Stockholm, Sweden using MSMs19 to provide less biased estimates by controlling for baseline 
confounding by indication and time-dependent confounding.
Results
There were 3,526 adult patients with CKD in the region of Stockholm known to specialist renal services who 
had a parathyroid hormone (PTH) twice above the upper reference range during the study inclusion period. 
The median age was 66.8 years and 64.6% were men (Web Table 7). The median PTH was 183 ng/L (interquar-
tile range [IQR] 150–265) and estimated glomerular filtration rate was 18.6 ml/min/1.73 m2 (IQR 9.4–27.1) at 
inclusion. At index date, 607 (17.2%) of the patients were receiving dialysis, and 415 (11.8%) had received a renal 
transplant. The baseline characteristics in relation to the EVOLVE study cohort are presented in the Web Table 8.
Cinacalcet treatment. During a median follow-up of 37 months (IQR 18–61), 435 (12.3%) patients ini-
tiated treatment with cinacalcet. The patients who were prescribed cinacalcet were younger (60.8 versus 67.7 
years among the non-users), more often had a history of cardiovascular disease, and were more often in dialysis 
(Table 1). Patients who were subsequently prescribed cinacalcet had higher PTH, phosphate and calcium levels 
than non-users. They were more users of active vitamin D, erythropoiesis stimulating agents, calcium supple-
ments, and phosphate binders at inclusion but less often users of angiotensin converting enzyme inhibitors and 
beta-blockers.
Treatment with cinacalcet was initiated after a median of 19 months from study inclusion. By the time cina-
calcet was started, the median PTH had risen to 636ng/L. Most patients were on dialysis (n = 272; 62.5%) or had 
a transplant (n = 54; 12.4%), though a substantial proportion (n = 109; 25.1%) were pre-dialysis patients with 
a mean eGFR of 14 ml/min/1.73 m2 (Table 2). Three and twelve months after initiating cinacalcet, the median 
PTH had dropped to 446 ng/L (95% Confidence interval: 408, 482) and 368 ng/L (95% CI: 318, 408), respec-
tively (Fig. 1, panels A–C). Serum calcium values increased slightly in the period preceding cinacalcet initiation, 
although they remained within the normal range even just before cinacalcet treatment started. After cinacalcet 
initiation, calcium dropped abruptly to somewhat lower values. Serum phosphate stayed rather constant during 
follow-up but increased from values just above the normal range to slightly higher values about six months before 
cinacalcet was started. Once cinacalcet was initiated, phosphate also dropped.
Cardiovascular event and all-cause mortality. In total, 1,498 patients (42.3%) experienced the com-
posite primary outcome (a new cardiovascular event) during follow-up resulting in a cardiovascular event rate of 
14.9/100 patient-years. Hospitalizations for new cardiovascular events were attributed to heart failure (n = 563; 
37.6%), followed by ischemic heart disease/myocardial infarction (n = 545; 36.4%), and cerebrovascular disease 
(n = 147; 9.8%) Only 102 patients (6.8%) died from cardiovascular death with no prior cardiovascular event. In 
total 1,130 patients (32.1%) died. Cardiovascular disease was the most common cause of death (n = 453; 40.1%), 
followed by metabolic disease (renal or endocrinological) (n = 354; 31.3%), cancer (n = 112; 9.9%) and infection 
(n = 69; 6.1%). The overall mortality rate was 9.6/100 person-years.
In the primary analysis of cardiovascular event risk, the unadjusted odds ratio (OR) for cinacalcet use versus 
non-use was 1.01 (0.82, 1.22) (Web Figure 1, Table 3). The model adjusted using inverse probability of treatment 
and censoring weights displayed lower cardiovascular odds among cinacalcet users (OR 0.67: 95% CI: 0.48, 0.93). 
The cause-specific ORs were rather similar for ischemic heart disease, heart failure and stroke (Subgroup analysis 
in Web appendix). The unadjusted OR of all-cause mortality associated with cinacalcet use was 0.98 (95% CI: 
0.82, 1.19). The fully weighted OR for all-cause mortality associated with cinacalcet use was 0.79; 95% CI: 0.56, 
1.11. There was no evidence of effect modification (P > 0.1) by age strata, gender, presence of diabetes mellitus, or 
dialysis status and therefore stratified analyses were not estimated (Web Appendix). Sensitivity analyses did not 
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meaningfully modify the magnitude or the direction of the associations observed (Web Tables 1–7). The results 
were consistent regardless of whether we used truncation of the treatment weights at 1,99th percentile, at treat-
ment weights >10, excluded patients who had the highest weights in the model, analysed only incident SHPT 
patients, included baseline blood pressure data, or analysed time on treatment.
Fractures. There were 309 (8.8%) patients who experienced a new fracture during follow-up which meant 
a fracture rate of 2.7/100 patient-years. The majority of the fractures were hip fractures (n = 122; 39.5%), fol-
lowed by fractures of the pelvis and lumbar region (n = 44; 14.2%), upper arm (n = 38; 12.3%), lower leg and 
knee (n = 30; 9.7%) and lower arm (n = 27; 8.7%). The unadjusted OR for fracture associated with cinacalcet 
use was 1.15 (95% CI: 0.80, 1.67). The estimate decreased slightly in the weighted model (OR 1.08; 95% CI: 
0.59, 1.95) with no evidence of association. There was weak evidence of interaction (p = 0.09) for fracture risk 
with the presence of diabetes mellitus. Among people with diabetes, cinacalcet treatment was associated with a 
No Cinacalcet 
(n = 3091)
New Cinacalcet 
use (n = 435) P-value
Characteristic Age, median years 67.7 (56–76) 60.8 (50–70) <0.001
Men 2025 (65.5) 252 (57.9) 0.01
Women 1066 (34.5) 183 (42.1)
Comorbidity Hypertension 1427 (46.2) 178 (40.9) 0.08
Cardiovascular disease 1338 (43.3) 142 (32.6) <0.001
Diabetes mellitus 675 (21.8) 86 (19.8) 0.48
Charlson comorbidity index, 
mean 3.96 (2.2) 3.68 (1.9) 0.11
Previous surgery for 
hyperparathyroidism 44 (1.4) 6 (1.4) 0.98
Previous fracture 400 (12.9) 49 (11.3) 0.57
Laboratory Parathyroid hormone, median 177 (147–243) 316 (202–548) <0.001
P-Phosphate, median 1.3 (1.1–1.6) 1.6 (1.3–2.0) <0.001
B-Haemoglobin 119.8 (17.1) 119.9 (15.4) 0.03
P-Albumin, median 35 (32–38) 35 (32–38) 0.03
P-Calcium, median 2.25 (2.17–2.34) 2.37 (2.25–2.50) <0.001
P-Creatinine, median 256 (191–394) 499 (286–739) <0.001
Albuminuria no 640 (31.8) 32 (22.2) 0.006
Albuminuria micro 367 (18.3) 21 (14.6)
Albuminuria macro 1,006 (50.0) 91 (63.2)
Medication ACEi or ARB 2237 (72.4) 272 (62.5) 0.001
Beta-blocker 2009 (65.0) 248 (57.0) 0.007
Vitamin D (active) 1,396 (45.2) 240 (55.2) 0.001
Vitamin D nutritional 193 (6.2) 13 (3.0) 0.27
Erythropoiesis stimul. agents 936 (30.3) 185 (42.5) 0.001
Calcium supplement 961 (31.1) 171 (39.3) 0.005
Phosphate binder 320 (10.4) 156 (35.9) <0.001
Prednisolone 790 (25.6) 86 (19.8) 0.050
RRT Dialysis 417 (13.5) 190 (43.7) <0.001
Renal transplantation 363 (11.7) 52 (12.0) 0.94
Outcomes
Cardiovascular event 1295 (41.9) 203 (46.7) 0.11
Hospitalization ischemic heart 
disease/myocardial infarction 502 (16.2) 43 (9.9) 0.19
Hospitalization heart failure 523 (16.9) 40 (9.2) 0.08
Hospitalization stroke 136 (4.4) 11 (2,5) 0.67
Hospitalization other 
cardiovascular 119 (3.8) 22 (5.1) 0.48
Cardiovascular death 15 (0.5) 87 (20.0) 0.02
All-cause mortality 993 (32.1) 137 (31.5) 0.79
Fracture 383 (11.9) 52 (16.8) 0.22
Table 1. Baseline Characteristics of the Chronic Kidney Disease Cohort According to Received Cinacalcet 
Treatment, Stockholm, Sweden 2006–2011. The variables are presented as number (percentages) if categorical 
and median (interquartile range, IQR) or mean (Standard deviation, SD) if continuous. ACEi (Angiotensin 
Converting Enzyme inhibitor), ARB (Angiotensin Receptor Blocker). eGFR (glomerular filtration rate 
estimated by CKD-EPI equation) in ml/min/1.73 m2, RRT (renal replacement therapy), P-values estimated by 
Kruskall-Wallis (Chi2) for categorical variables and Pearson Chi2 for continuous variables.
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non-significantly lower odds of a new fracture (OR 0.42; 95% CI: 0.15, 1.19). The association was observed in the 
opposite direction for those without diabetes (OR 1.40: 0.78, 2.51). No effect modification was seen for age strata, 
sex or dialysis/transplantation status at baseline (Web Appendix).
Discussion
In this analysis of referred CKD patients in the region of Stockholm with secondary hyperparathyroidism, we 
found that initiation of cinacalcet was associated with a lower odds of cardiovascular events compared with no 
use. No differences in all-cause mortality or fracture risk were observed between cinacalcet users and non-users.
Observational studies have consistently showed that markedly elevated PTH levels are associated with worse 
outcomes both in dialysis patients20 and after renal transplantation21. However, there is also evidence that low 
PTH and adynamic bone disease predispose to increased vascular calcification and higher mortality20,22. Such 
findings have raised concerns about over-suppressing PTH with cinacalcet, especially in patients with preserved 
renal function23. In our “real world” observational study, patients that initiated cinacalcet had progressively 
increasing PTH levels with a median value above the Kidney Disease improving global Outcomes (KDIGO) 
guideline targets at the time of initiation. After cinacalcet initiation, median PTH concentration dropped within 
KDIGO targets and both calcium and phosphate levels normalized.
It is noteworthy that PTH and calcium levels at initiation of cinacalcet in our study were very similar to the 
baseline values of EVOLVE patients24, but phosphate levels were slightly higher. Patients included in our study 
were on average 10 years older, as displayed in Web Table 9. Although they less often had diabetes mellitus or 
hypertension diagnosed, our patients had a higher prevalence of heart failure, myocardial infarction and stroke 
at the time of cinacalcet initiation. However, our patient population was more heterogeneous because we con-
sidered any new cinacalcet user in the region with CKD stage 3+ and renal replacement therapy (haemodialysis, 
peritoneal dialysis and renal transplantation). Therefore our results expand the population originally targeted in 
the randomized trial.
Although the results of the EVOLVE study did not attain statistical significance for its primary outcome, 
prespecified secondary analyses (using both time-on-treatment and inverse probability weighting) and 
post-hoc intention to treat analyses adjusting for a statistically significant difference in age between the treated 
and non-treated suggested a beneficial effect on cardiovascular events10, especially among elderly patients24. 
Furthermore, combined post hoc meta-analysis of four earlier randomized controlled trials indicated lower rates 
of hospitalization for cardiovascular events25. Our study agrees with these observations, and our estimates are 
At Cinacalcet initiation (n = 435)
Timing of cinacalcet initiation Months after baseline, mean (SD) 22.8 (17.0)
Comorbidity before initiation Charlson comorbidity index 3.68 (1.9)
New fracture before cinacalcet initiation 18 (4.1)
New cardiovascular event before cinacalcet initiation 76 (17.5)
Laboratory values Parathyroid hormone, median (IQR) 636 (436–860)
P-Phosphate, median (IQR) 1.8 (1.4–2.2)
B-Haemoglobin 119.5 (15.1)
P-Albumin 34.0 (4.3)
P-Calcium, median (IQR) 2.45 (2.28–2.59)
Albuminuria (%)
none 30 (12.0)
micro 43 (17.1)
macro 178 (70.9)
Medication Use of ACEi or ARB 283 (65.1)
Use of Beta-blocker 284 (65.3)
Use of Vitamin D (active) 316 (72.6)
Use of Vitamin D supplement 14 (3.2)
Use of erythropoiesis stimulating agents 212 (48.7)
Use of Calcium supplement 196 (45.1)
Use of Phosphate binder 316 (72.6)
Use of Prednisolone 100 (23.0)
Renal replacement therapy (RRT) No RRT 109 (25.1)
Dialysis 272 (62.5)
Renal transplantation 54 (12.4)
Table 2. Characteristics at the Time of Cinacalcet initiation in Chronic Kidney Disease Patients, Stockholm, 
Sweden 2006–2012. The variables are presented as number (percentages) if categorical and median 
(interquartile range, IQR) or mean (Standard deviation, SD) if continuous. eGFR (glomerular filtration rate 
estimated by CKD-EPI equation) in ml/min/1.73 m2, ACEi (Angiotensin Converting Enzyme inhibitor), ARB 
(Angiotensin Receptor Blocker).
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close to those found in the meta-analysis. In contrast to EVOLVE, we did not include death from any cause in our 
primary end-point, but only cardiovascular death and events. We in fact show that cinacalcet users had a similar 
unadjusted cardiovascular event risk as the non-users, but that after careful adjustment for past and current clin-
ical history, cincalcalcet treatment was associated with lower incidence of cardiovascular events.
Figure 1. Development of parathyroid hormone (A), corrected calcium (B) and phosphate (C) among referred 
CKD patients in Stockholm, Sweden 2006–2012 before and after Cinacalcet initiation. Below figure: Parathyroid 
hormone levels (PTH) in ng/L with 95% confidence interval. M(month). Negative signs indicate that the month 
is prior to treatment initiation and positive numbers that the month is after the treatment initiation.
Crude OR 
(n = 3526)
Model 1* 
(n = 3339)
Model 2 ** (main)
(n = 3339)
Model 3# 
(n = 3339)
Cardiovascular event 1.01 (0.83–1.22) 0.52 (0.34–0.81) 0.67 (0.48–0.93) 0.68 (0.51–0.92)
All-cause mortality 0.98 (0.82–1.19) 0.73 (0.49–1.07) 0.79 (0.56–1.11) 0.83 (0.62–1.10)
Fracture 1.15 (0.80–1.67) 1.06 (0.58–1.95) 1.08 (0.59–1.98) 1.15 (0.67–1.97)
Table 3. Odds of Outcomes Associated with Cinacalcet Treatment in Chronic Kidney Disease Patients, 
Stockholm, Sweden 2006–2012. All results presented as Odds ratios OR) with 95% confidence intervals. Only 
months with complete information are included. Cardiovascular event (non-fatal or fatal myocardial infarction, 
cerebrovascular event, angina, congestive heart failure or peripheral arterial disease). *Fully-weighted model 
with no truncation of weights and adjustment for baseline variables in the MSM, **Fully-weighted model with 
truncation at 1,99th percentile and adjustment for baseline variables in the MSM, #Fully-weighted model with 
truncation at 1,99th percentile without adjustment for baseline variables in the MSM. The adjustment variables 
included in the stabilized weights (treatment and censoring weights) are presented in the Web Appendix. In 
short they included history of comorbid conditions, age and sex, routine laboratory variables at inclusion 
and monthly during follow-up, relevant medication at inclusion and monthly during follow-up, Charlson 
comorbidity index at inclusion and during follow-up, PTH-assay, dialysis and transplantation, and treatments 
3–12 months before the current month.
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The weaker association with mortality observed in our study disagrees with a previous large observational 
report in dialysis patients using traditional statistical methods which found a lower risk for all-cause and cardio-
vascular mortality associated with cinacalcet14. Cinacalcet use in that study was associated with lower mortality in 
the unadjusted models. We believe this can be attributed to time-dependent confounding, given that they included 
prevalent dialysis patients and were a subset of survivors with lower cardiovascular risk. Time-dependent con-
founding may also have played a role later as those predicted to live long enough to benefit from cinacalcet were 
preferentially selected. This bias cannot be adequately addressed by traditional statistical models, but is accounted 
for in our analysis by using inverse probability weights.
Our results failed to show any association between cinacalcet use and the risk of fractures. At least two previ-
ous studies have suggested lower fracture incidence among cinacalcet treated patients25,26. The patients in both 
of these preceding studies were on average about 10 years younger than our patients, and our cohort included a 
broad mix of patients with different stages of CKD, undergoing dialysis and renal transplantation. It is possible 
that the fracture risk differs between these populations, but the event rate in our study was low compared with 
the other two studies and the confidence intervals wide, which prevented us from performing stratified analyses. 
Competing risk of death may have reduced fracture incidence more in our older population. It is also possible 
that our prediction of treatment models worked less well for fractures, since many of the characteristics related to 
fracture risk such as frailty and lean body mass are not captured among diagnostic codes. Finally, PTH is a poor 
predictor of bone histology and there is a big overlap where patients of normal-elevated PTH values may have 
either increased or decreased bone turnover27.
In CKD-related mineral bone disorder, all the disturbances in calcium, phosphorus and PTH must be collec-
tively considered when selecting the appropriate treatment28. While our study does not aim to compare different 
SHPT management strategies (active and native vitamin D, vitamin D analogues, phosphate lowering drugs, 
and parathyroidectomy) we believe that our results should be interpreted in the context of the overall improved 
mineral balance observed in the cinacalcet users. The association between cinacalcet use and lower cardiovascu-
lar events may have been mediated through better control of phosphate, calcium, PTH and/or all of them. In the 
newly updated KDIGO guidelines on CKD-related mineral bone disorder it is suggested that patients requiring 
PTH-lowering therapy could be treated by calcimimetics, calcitriol, vitamin D analogues or any appropriate com-
bination of these treatments29. The pathophysiological mechanisms of the relationship between improvement in 
the mineral bone disorder axis and cardiovascular disease explain why our results favour our primary end-point 
more than all-cause mortality, where any positive association ought to be mediated via improved cardiovascular 
health and not through other mechanisms such as improvement of infection or cancer-related mortality.
There are several strengths to our study. First, due to the complete coverage of the health care utilization of our 
region we were able to include referred CKD Stage G3+ patients and with richness of information of unprece-
dented precision and virtually no loss to follow up. Cinacalcet was first introduced to the Swedish market in 2005. 
Since we excluded patients who were prescribed cinacalcet before 2006, prevalent patients with long-standing 
severe SHPT were not included, allowing us to thus construct an inception cohort. In Sweden at the time, cina-
calcet was prescribed at the discretion of the treating nephrologist. Due to the poor guidelines for CKD-related 
mineral bone disorder during the first years of the study there were no specified recommendations on when 
cinacalcet could be prescribed for SHPT. Often cinacalcet was used in the region as an option before, or instead of 
parathyroidectomy. Cinacalcet was included in the general reimbursement for patients and thus dispensed a very 
low cost or no cost. Quite surprisingly, a relatively large proportion was prescribed cinacalcet off-label, already 
before dialysis initiation. However, due to differences in clinical practice between nephrologists and clinics in the 
region there was a wide variation of when and to whom the drug was prescribed. Our advanced statistical analysis 
made use of these differences. The EVOLVE study was not published until 2012 and it is unlikely that it would 
have influenced prescription patterns in our study.
As with all observational studies, there are also limitations. Some factors influencing a doctor’s decision to 
treat are difficult to measure, e.g. “frailty”. Thus, residual unmeasured confounding may have affected our results, 
but, the use of a rich dataset with all recorded laboratory values ever analysed during the time period, and exten-
sive linkages to other healthcare sources minimized this as much as possible. However, we acknowledge for 
instance the lack of measurements of 25-OH-vitamin D levels or alkaline phosphatase. We also mostly lacked 
information on clinical measures such as blood pressure, smoking status and body mass index. However, in sen-
sitivity analyses including patients with available blood pressure data at baseline, we found no major difference in 
the size or direction of the estimates.
In conclusion, in this analysis of a large, regional inception cohort of CKD stage 3+ patients with SHPT, 
treatment with cinacalcet was associated with lower risk of cardiovascular events. In general, those treated with 
cinacalcet had progressive disturbances in calcium, phosphate and PTH before treatment was started, which were 
improved after cinacalcet initiation. This study adds real-world support that treating SHPT with cinacalcet may 
have beneficial effects on cardiovascular outcomes. It suggests that the results from the EVOLVE are applicable to 
the wider, secondary care CKD population – given that generalizability is always a concern about evidence from 
randomized controlled trials. However, it is not possible from our study to compare cinacalcet with other treat-
ments that may be equally effective to correct SHPT and other biochemical abnormalities.
Methods
Study population, exposure and measurements. This study is based on the Stockholm CREAtinine 
Measurements (SCREAM) project30, a healthcare-utilization cohort in Stockholm, Sweden between 2006–2012 
described in more detail elsewhere30. We selected all adult (≥18 years) individuals with CKD Stage G3 + (esti-
mated glomerular filtration rate <60 ml/min/1.73 m2) attending secondary care nephrology who had ever had a 
PTH test twice above the upper reference limit, ≥130 ng/L and who had never used cinacalcet (Web Figures 2). 
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The study protocol was approved by the ethical committee in Stockholm. According to Swedish law, written con-
sent is not required because quality control is an inherent element of hospital health care.
The first date of a pharmacy dispensation (ascertained by the National Registry for Dispensed drugs) of cin-
acalcet was used to determine date of treatment initiation. Study covariates considered included age, sex, and a 
variety of laboratory tests, comorbidities and medications. All consecutive laboratory tests, performed in con-
nection with encounters in primary care, outpatient specialist care or hospital care, were extracted from the three 
laboratories that provide services to the region. For this study we extracted all available laboratory results for 
plasma PTH, creatinine, phosphate, calcium, haemoglobin, albumin, c-reactive protein, and proteinuria. PTH 
was measured by four different methods at the three laboratories. All three laboratories used second generation 
assays which also measured the PTH fragments and reported the results in ng/L. All serum creatinine measure-
ments were standardized to isotope dilution mass spectrometry standards. Glomerular filtration rate was esti-
mated by the CKD-EPI equation31.
Comorbidities and surgical procedures were identified by ICD-10 codes issued in primary care health records, 
specialized out-patient care, and in-hospital care. We calculated co-morbidity history at baseline and a combined 
Charlson comorbidity index32. Concurrent medication use considered all consecutive pharmacy purchases of 
angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, calcium supplements, 
non-calcium containing phosphate binders, active vitamin D, nutritional vitamin D (inactive), erythropoiesis 
stimulating agents, and prednisolone or other steroids (see Web Appendix for definitions, ICD-10 and ATC 
codes).
Study outcomes. The primary outcome was the composite of non-fatal and fatal cardiovascular events (hos-
pitalization or death caused by myocardial infarction, angina pectoris, congestive heart failure, cerebrovascular 
disease, and peripheral arterial disease). Secondary outcomes were all-cause mortality and any new fracture dur-
ing follow-up.
Statistical analysis. The data were analysed as per protocol, decided a priori, and based upon current 
knowledge of factors likely to influence clinical history and treatment decisions. Patients were followed from 
the first PTH twice above the reference until end of follow-up. They were regarded unexposed until the first 
dispensation date of cinacalcet and exposed all months thereafter (applying an intention-to-treat approach). 
Both time-fixed and time-dependent variables were considered. The time-fixed variables were age, sex, history 
of diabetes, cardiovascular disease, hypertension, and previous surgery for hyperparathyroidism at index date. 
Continuous time-dependent variables (haemoglobin, albumin, phosphate, creatinine, and estimated glomerular 
filtration rate) were categorized into quintiles of distribution. PTH assay was used as a categorical time-varying 
covariate for the four different types of analyses used. Medication, renal transplantation, dialysis treatment and 
Charlson comorbidity index were used as categorical, time-varying covariates.
We estimated the stabilized inverse probability weights of treatment monthly and accumulated until treatment 
initiation using a logistic regression model which modelled the association of cinacalcet use with all time-fixed 
and time-varying covariates described above plus a time covariate33. We calculated the stabilized censoring 
weights similarly. To reduce the risk of extreme weights affecting our results, we truncated the treatment weights 
at the 1,99th percentile (0.096, 2.76)33 and used the truncated weights in all our main analyses. The variables used 
in the analyses, and distributions of treatment weights with and without truncation at different levels are pre-
sented in the Web Appendix. Our final weighted MSM included the stabilized treatment and censoring weights 
adjusting for past and current confounders of treatment. We also performed interaction tests for possible effect 
modification by some predetermined subgroups (age above and below 65 years, sex, history of diabetes and renal 
replacement therapy at inclusion). We tested the positivity assumption by analysing cinacalcet use for different 
categories of PTH. There were both cinacalcet treated and non-treated in every PTH quintile both at baseline and 
during follow-up (Web Figure 3). Finally, we performed several sensitivity analyses including “time on treatment”, 
including more covariates and different model specifications (Web Tables 1–6). All analyses were performed 
using Stata 12 (StataCorp).
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